Carisma Therapeutics Gets FDA Clearance To Start Phase 1 Study Of CT-0525 In Solid Tumors

(RTTNews) - Clinical stage biopharmaceutical company Carisma Therapeutics Inc. (CARM) Tuesday said it received clearance from the Food and Drug Administration (FDA) to initiate Phase 1 study of its drug candidate CT-0525 to treat solid tumors.

Carisma said it expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.

CT-0525 is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).